Mesenchymal Stem Cells (MSCs) — Competitive Intelligence Brief

Mesenchymal Stem Cells (MSCs) (Mesenchymal Stem Cells (MSCs)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Regenerative Medicine, Immunology, Orthopedics.

marketed Cell therapy Regenerative Medicine, Immunology, Orthopedics Small molecule

Target snapshot

Mesenchymal Stem Cells (MSCs) (Mesenchymal Stem Cells (MSCs)) — The Cleveland Clinic. Mesenchymal stem cells exert therapeutic effects through immunomodulation, anti-inflammatory signaling, and tissue repair via paracrine secretion of bioactive factors and direct cell-to-cell interactions.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mesenchymal Stem Cells (MSCs) TARGET	Mesenchymal Stem Cells (MSCs)	The Cleveland Clinic	marketed	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
MC	MC	Aivita Biomedical, Inc.	marketed	Mesenchymal stem cell therapy
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19
Cord blood	Cord blood	New York Medical College	marketed	Hematopoietic stem cell therapy
Licartin and CIK	Licartin and CIK	Tianjin Medical University Cancer Institute and Hospital	marketed	Monoclonal antibody (Licartin); Adoptive cell therapy (CIK)	HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)
hUCB	hUCB	StemCyte Taiwan Co., Ltd.	marketed	Allogeneic hematopoietic stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

1. Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
2. Bone Therapeutics S.A · 1 drug in this class
3. DiscGenics, Inc. · 1 drug in this class
4. Celavie Bioscences, LLC · 1 drug in this class
5. China Spinal Cord Injury Network · 1 drug in this class
6. City of Hope Medical Center · 1 drug in this class
7. Brainstorm-Cell Therapeutics · 1 drug in this class
8. Dr. Grant M. Pagdin · 1 drug in this class
9. FDA Office of Orphan Products Development · 1 drug in this class
10. Biosolution Co., Ltd. · 1 drug in this class